Results for this period
Third quarter1 October 2025 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Supply of HGF drug substance in line with Claris Biotherapeutics' development progress, receipt of technology access fees and recognition of revenue for the relevant period.
Disclosure of material events, etc. is included. Although conditions giving rise to material doubt exist due to continuing operating losses, negative cash flow from operating activities and delays in the timing of regulatory applications, among other factors, the Company determined that there is currently no material uncertainty regarding the going-concern assumption. There are no matters to report in the notes regarding the going-concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025 to 30 June 2026 |
| Net Sales | ¥323 million (YoY +501.0%) |
| Operating profit | ¥-633 million |
| Ordinary income | ¥-628 million |
| Profit attributable to owners of the parent | ¥-631 million |
| Net income per share | ¥(84.44) |
| Equity ratio | End of the current fiscal period 60.9 / End of previous period 61.5 |
| Total assets | ¥1,996 million |
| Net assets | ¥1,252 million |
| Full-year earnings forecast | Net Sales ¥332 million (YoY +360.4%) / Operating profit ¥-1,018 million / Ordinary income ¥-1,018 million / Net income ¥-1,020 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥0 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses on Shares of Affiliates ¥1,797 thousand |
| Disclosure regarding the going concern assumption | Disclosure of material events, etc. is included. Although conditions giving rise to material doubt exist due to continuing operating losses, negative cash flow from operating activities and delays in the timing of regulatory applications, among other factors, the Company determined that there is currently no material uncertainty regarding the going-concern assumption. There are no matters to report in the notes regarding the going-concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | At a meeting of the Board of Directors held on 15 July 2026, the Company resolved to submit a proposal for a reduction in the amounts of stated capital and capital reserves, together with an appropriation of surplus, to an extraordinary general meeting of shareholders scheduled for 28 August 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (participants not specified) |
| Issued Shares at Period-End | 8,383,200 |
| Treasury Shares at Period-End | 183 |
| Factors Behind Changes in Business Performance | Supply of HGF drug substance in line with Claris Biotherapeutics' development progress, receipt of technology access fees and recognition of revenue for the relevant period. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company supplied HGF drug substance in line with Claris Biotherapeutics' development progress and recognized fixed annual technology access fees as revenue for the relevant period.